Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,267
Employees75,267
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,267
Employees75,267

NVS Key Statistics

Market cap
316.31B
Market cap316.31B
Price-Earnings ratio
22.24
Price-Earnings ratio22.24
Dividend yield
1.96%
Dividend yield1.96%
Average volume
2.79M
Average volume2.79M
High today
$156.36
High today$156.36
Low today
$155.11
Low today$155.11
Open price
$155.39
Open price$155.39
Volume
1.38M
Volume1.38M
52 Week high
$170.46
52 Week high$170.46
52 Week low
$112.34
52 Week low$112.34

NVS News

Zacks 2d
Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition - Zacks Investment Research

...

Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition - Zacks Investment Research
Benzinga 3d
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push

The acquisition would add Myricx’s N-myristoyltransferase inhibitor (NMTi) payload platform, which is designed to deliver targeted cancer therapies with a novel...

Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push
TipRanks 3d
Novartis to Acquire Myricx Bio for $1.5B to Boost Cancer Drugs; NVS Stock Falls

Swiss pharmaceutical company Novartis (NVS) agreed to acquire UK-based private biotech firm Myricx Bio for $1.5 billion, including $1.1 billion upfront in cash....

Analyst ratings

46%

of 28 ratings
Buy
35.7%
Hold
46.4%
Sell
17.9%

More NVS News

TipRanks 3d
Novartis agrees to acquire Myricx Bio for up to $1.5B

Novartis (NVS) announced that it has entered into an agreement to acquire Myricx Bio, a privately held UK-based biotechnology company developing a new class of...

TipRanks 3d
Novartis to acquire Myricx Bio for $1.1B upfront

Myricx Bio, a UK-headquartered biotech company, announced that it has reached agreement to be acquired by Novartis (NVS) for up to $1.5B including $1.1B cash up...

The Wall Street Journal 3d
Novartis to Buy Myricx Bio for Up to $1.5 Billion

Novartis will pay $1.1 billion upfront for Myricx Bio, with up to $400 million in potential additional payments. Mike Blake / Reuters Novartis NOVN -0.08 %decr...

Novartis to Buy Myricx Bio for Up to $1.5 Billion
Seeking Alpha 6d
Novartis gene therapy Itvisma approved in EU for spinal muscular atrophy

Novartis (NVS) on Thursday announced that the European Commission approved its gene therapy. Itvisma (onasemnogene abeparvovec) for children aged two years and...

Novartis gene therapy Itvisma approved in EU for spinal muscular atrophy
TipRanks 7d
Novartis receives EC approval for Itvisma for spinal muscular atrophy

Novartis (NVS) announced that the European Commission, EC, has approved Itvisma for the treatment of children two years and older, teens and adults living with...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.